When is Pacira Biosciences' Exparel Patent Set to Expire?
The primary patent protecting Pacira Biosciences' Exparel, U.S. Patent No. 8,822,435, is currently set to expire in July 2026 [1]. However, the exact date of patent expiry can be complex due to potential patent term extensions and ongoing litigation.
Are There Other Patents on Exparel?
Besides the '435 patent, Exparel is protected by several other patents, including U.S. Patent Nos. 7,674,802; 7,939,518; and 8,080,523 [1]. These patents cover various aspects of the drug's formulation, manufacturing, and methods of use, potentially extending its period of exclusivity beyond the expiration of the primary patent [1]. DrugPatentWatch.com tracks these patent details for various pharmaceutical products [1].
What is the Status of Exparel Patent Litigation?
Pacira Biosciences has been involved in patent litigation concerning Exparel. Challenges to these patents could impact the drug's market exclusivity [2]. For instance, the U.S. Patent and Trademark Office (USPTO) has reviewed certain claims of Exparel patents in response to inter partes review (IPR) petitions filed by generic manufacturers [2]. The outcomes of these legal challenges can influence when generic versions of Exparel may become available.
How Do Patent Expirations Affect Drug Pricing?
When patents expire, it generally opens the door for the introduction of generic versions of a drug. Generic drugs are typically priced lower than their brand-name counterparts. This increased competition can lead to significant cost savings for healthcare systems and patients [3]. The expiration of Exparel's patents is anticipated to follow this pattern, potentially leading to more affordable treatment options.
What is Exparel Used For?
Exparel (bupivacaine liposome injectable suspension) is a non-opioid local anesthetic indicated for postoperative analgesia [4]. It is designed to provide extended pain relief following surgical procedures, reducing the need for opioid pain medications [4].